anesthesia glp-1 news Are Serious Risks of Semaglutide and Other Agonists Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia GLP-1 RA guidance roundup Health Canada Reviewing GLP-1 Aspiration

Drugs 61 (11), 16251660

A recent study shows people with obesity taking GLP-1 drugs are 20% less likely to suffer a cardiovascular event, and studies are under way for their use to treat the liver disease non-alcoholic steatohepatitis, as well as the neurodegenerative conditions Parkinsons and Alzheimers

Over 72 weeks patients without diabetes lost 15%, 19%, and 21% of body weight on the 5, 10, and 15 mg weekly SQ injections, respectively

Diabetes Care, 47(6), 10201027

About this article Cite this article Lu, Z., Liu, N., Huang, H

When Associates focus on helping people make informed choices, they create stronger relationships, better customer experiences, and lasting momentum